iPSC-based research in ALS precision medicine
- PMID: 37267911
- DOI: 10.1016/j.stem.2023.05.008
iPSC-based research in ALS precision medicine
Abstract
Clinical trials in amyotrophic lateral sclerosis (ALS) are challenged by the lack of pre-clinical models and biomarkers of disease onset and progression. In this issue, Morimoto et al. use induced pluripotent stem cell (iPSC)-derived motor neurons from patients with ALS to study therapeutic mechanisms of ropinirole in a clinical trial and identify treatment responders.
Copyright © 2023 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests The authors declare no competing interests.
Comment on
-
Phase 1/2a clinical trial in ALS with ropinirole, a drug candidate identified by iPSC drug discovery.Cell Stem Cell. 2023 Jun 1;30(6):766-780.e9. doi: 10.1016/j.stem.2023.04.017. Cell Stem Cell. 2023. PMID: 37267913 Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
